BioCentury
ARTICLE | Clinical News

CPI-444: Phase I data

October 17, 2016 7:00 AM UTC

Data from 48 solid tumor patients from 4 cohorts in the dose-selection portion of an open-label, international Phase I/Ib trial showed that oral CPI-444 alone and in combination with Tecentriq atezolizumab was well tolerated, with 1 patient experiencing a possibly treatment-related serious adverse event. Patients in the dose-selection portion received twice-daily 100 mg CPI-444 for 14 days; twice-daily 100 mg CPI-444 for 28 days; once-daily 200 mg CPI-444 for 14 days; or twice-daily 50 or 100 mg CPI-444 for 14 days plus Tecentriq in 28-day cycles. Corvus said it selected twice-daily 100 mg CPI-444 for 28 days as the dose for both the single agent and Tecentriq combination arms in the second part of the trial, which will enroll 140 additional patients in 10 cohorts. Each cohort may be expanded based on efficacy. Data were presented at the European Society for Medical Oncology meeting in Copenhagen. The company plans to report efficacy data from the dose-selection portion later this year. Corvus has exclusive, worldwide rights to CPI-444 from Vernalis (see BioCentury, March 9, 2015 & Dec. 7, 2015). ...